Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Kiwi COVID 19 Vaccine Developer In Biobead Tech Collaboration

COVID-19 Vaccine Corporation (CVC), New Zealand’s COVID-19 vaccine development company, is collaborating with Dr Iain Hay, senior lecturer in Biological Sciences at the University of Auckland and his group. The university’s commercialisation arm, Auckland UniServices, has facilitated the collaboration.

Dr Hay is constructing the main biobead vaccine components for inclusion in CVC’s COVID-19 vaccine. Dr Hay, who is an expert bacterial molecular biologist, has had previous experience with the biobead technology. The unique biobead technology was developed in New Zealand by PolyBatics.

“It’s a genuine pleasure to be collaborating with the University of Auckland and Iain Hay in particular. CVC endeavours to use the best expertise available and wherever possible, in New Zealand. It’s a huge advantage to us that Iain has previous experience with biobead technology,” says Dr Robert Feldman, chief executive of CVC.

“We are pleased that CVC has chosen to partner with the University of Auckland on a project that adds to the significant portfolio of projects that the University of Auckland has contributed to in the fight against COVID-19,” says Will Charles, executive director of commercialisation at UniServices.

“Molecular biology skills are critical in effective vaccine development and we greatly appreciate how Iain and his team have swung in behind the creation of CVC’s vaccine. It is another example of the spirit of collaboration we are experiencing from scientists and technologists across New Zealand to help combat the challenge of this dangerous disease,” comments Dr Andy Herbert, CVC chief operating officer and chief scientific officer.

Dr Feldman says the company aims to complete its first human trial of the new vaccine early in 2022.

The CVC team includes Dr Robert Feldman, a global biotech expert and medical doctor with vaccine and start-up experience; Dr Andy Herbert, an expert in vaccine development and manufacturing; Tara Creaven-Capasso, a regulatory, quality and biotech expert with extensive international experience; and Helen Teale, who has global clinical trial management expertise. The company is chaired by Douglas Pharmaceuticals’ managing director, Jeff Douglas.

© Scoop Media

Business Headlines | Sci-Tech Headlines


Snail's Pace: Aucklanders Face Frustrating Commute Over Harbour Bridge

Journeys into Auckland's CBD took longer than usual as traffic banked up around the damaged Harbour Bridge. More>>


Statistics New Zealand: COVID-19 Sees Record 12.2 Percent Fall In New Zealand’s Economy

Gross domestic product (GDP) fell by 12.2 percent in the June 2020 quarter, the largest quarterly fall recorded since the current series began in 1987, as the COVID-19 restrictions in place through the quarter impacted economic activity, Stats NZ said ... More>>


Climate: Scientists Release ‘Blueprint’ To Save Critical Ecosystems And Stabilize The Earth’s Climate

A group of scientists and experts produced the first comprehensive global-scale analysis of terrestrial areas essential for biodiversity and climate resilience, totaling 50.4% of the Earth's land. The report was published in Science Advances ... More>>


MPI: Independent Review Launched Into Assurances For Safe Transport Of Livestock By Sea

The Ministry for Primary Industries (MPI) has launched an independent review of the assurances it receives for the safe transport of livestock by sea. MPI Director-General Ray Smith says Mike Heron QC has been appointed to lead the review, which is expected ... More>>


Computers: New Zealand PC Market Grows Nearly 40% Due To Work From Home Demand

COVID-19 had large impacts on demand for PCs as businesses prepared for lockdowns by purchasing notebooks to mobilise their workforce. In the second quarter of 2020, New Zealand's Traditional PC market experienced a 39.7% year-on-year (YoY) growth ... More>>


Ministry of Health: Public Transport Distancing Requirements Relaxed

Physical distancing requirements on public transport have been reviewed by the Ministry of Health to determine whether they are still required at Alert Level 2 (or below). The Ministry’s assessment is that mandatory face covering and individuals tracking ... More>>


NZHIA: New Zealand Hemp Industry Set To Generate $2 Billion Per Annum And Create 20,000 Jobs

A new report says a fully enabled hemp industry could generate $2 billion in income for New Zealand by 2030, while also creating thousands of new jobs. Written by industry strategist Dr Nick Marsh, the report has prompted calls from the New Zealand Hemp ... More>>


Stats NZ: One In 14 Employed People Report High Risk Of Losing Jobs

About one in 14 workers say they expect to lose their job or business by mid-2021, Stats NZ said today. A survey of employed people in the June 2020 quarter showed 7 percent felt there was a high or almost certain chance of losing their job or business ... More>>

ASB Quarterly Economic Forecast: NZ Economy Doing Better Than Expected, But Challenges Remain

August lockdown estimated to have shaved 8% off NZ’s weekly GDP, and 0.5% off annual GDP Economy now expected to shrink 5% (year-on-year) by end of 2020 Unemployment rate now expected to peak at 7.2% The latest ASB Quarterly Economic Forecast is less ... More>>


SAFE: Live Export Ship Carrying 5,800 New Zealand Cows Goes Missing In East China Sea

Livestock carrier Gulf Livestock 1 sent a distress signal at 4:45am NZT yesterday in the East China Sea. The area is affected by Typhoon Maysak. At 4pm a patrol plane spotted a lifeboat - with no people in it - and a man in lifejacket nearby. The ship ... More>>


FMA: Kiwisaver Fees Don't Match Performance

The Financial Markets Authority (FMA) today published an independent report into the passive and active investment management styles [i] used by KiwiSaver providers. The FMA commissioned MyFiduciary to test the extent that KiwiSaver providers were ... More>>